XML 40 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities    
Net loss $ (47,480) $ (20,668)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 3,737 707
Change in fair value of redeemable convertible preferred stock tranche liability (11,718)
Investment amortization (370)  
Foreign currency gain from remeasurement 245 359
In-process research and development expenses 9,158
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 10,260 1,352
Long term assets (2,563) 2,524
Accounts payable 318 (167)
Accrued liabilities 3,368 964
Accounts payable and accrued liabilities, related party (168) 143
Long-term liabilities 7
Net cash used in operating activities (36,072) (14,098)
Cash flows from investing activities:    
Assets acquired in asset acquisition including cash 8,279
Cash used for purchase of in-process research and development from a related party (201)
Purchase of marketable securities (114,970)
Net cash provided by (used in) investing activities (114,970) 8,078
Cash flows from financing activities:    
Proceeds from initial public offering, net issuance costs 83,144
Proceeds from issuance of redeemable convertible preferred stock and related tranche rights, net of issuance costs 93,939 4,925
Proceeds from exercise of stock options 149
Net cash provided by financing activities 177,232 4,925
Effect of exchange rate changes on cash 245 359
Net change in cash and cash equivalents 26,435 (736)
Cash and cash equivalents at beginning of period 20,487 21,223
Cash and cash equivalents at end of period 46,922 20,487
Supplemental disclosure of cash flow information:    
Conversion of redeemable convertible preferred stock to common stock 152,759
Redeemable convertible preferred stock accretion $ 1,503